52722 Federal Register / Vol. 62, No. 196 / Thursday, October 9, 1997 / Notices

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and

Mergers of Bank Holding Companies

The companies listed in this notice

have applied to the Board for approval,

pursuant to the Bank Holding Company

Act of 1956 (12 U.S.C. 1841 et seq.)

(BHC Act), Regulation Y (12 CFR Part

225), and all other applicable statutes

and regulations to become a bank

holding company and/or to acquire the

assets or the ownership of, control of, or

the power to vote shares of a bank or

bank holding company and all of the

banks and nonbanking companies

owned by the bank holding company,

including the companies listed below.

The applications listed below, as well

as other related filings required by the

Board, are available for immediate

inspection at the Federal Reserve Bank

indicated. The application also will be

available for inspection at the offices of

the Board of Governors. Interested

persons may express their views in

writing on the standards enumerated in

the BHC Act (12 U.S.C. 1842(c)). If the

proposal also involves the acquisition of

a nonbanking company, the review also

includes whether the acquisition of the

nonbanking company complies with the

standards in section 4 of the BHC Act.

Unless otherwise noted, nonbanking

activities will be conducted throughout

the United States.

Unless otherwise noted, comments

regarding each of these applications

must be received at the Reserve Bank

indicated or the offices of the Board of

Governors not later than November 1,

1997.

A. Federal Reserve Bank of

Philadelphia (Michael E. Collins, Senior

Vice President) 100 North 6th Street,

Philadelphia, Pennsylvania 19105-1521:

1. MBNA Corporation, Wilmington,

Delaware; to acquire 100 percent of the

voting shares of MBNA Amercia Bank

(Delaware), Wilmington, Delaware.

Board of Governors of the Federal Reserve

System, October 3, 1997.

William W. Wiles,

Secretary of the Board.

[FR Doc. 97–26736 Filed 10–8–97; 8:45 am]

BILLING CODE 6210–01–F

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and

Mergers of Bank Holding Companies

The companies listed in this notice

have applied to the Board for approval,

pursuant to the Bank Holding Company

Act of 1956 (12 U.S.C. 1841 et seq.)

(BHC Act), Regulation Y (12 CFR Part

225), and all other applicable statutes

and regulations to become a bank

holding company and/or to acquire the

assets or the ownership of, control of, or

the power to vote shares of a bank or

bank holding company and all of the

banks and nonbanking companies

owned by the bank holding company,

including the companies listed below.

The applications listed below, as well

as other related filings required by the

Board, are available for immediate

inspection at the Federal Reserve Bank

indicated. The application also will be

available for inspection at the offices of

the Board of Governors. Interested

persons may express their views in

writing on the standards enumerated in

the BHC Act (12 U.S.C. 1842(c)). If the

proposal also involves the acquisition of

a nonbanking company, the review also

includes whether the acquisition of the

nonbanking company complies with the

standards in section 4 of the BHC Act.

Unless otherwise noted, nonbanking

activities will be conducted throughout

the United States.

Unless otherwise noted, comments

regarding each of these applications

must be received at the Reserve Bank

indicated or the offices of the Board of

Governors not later than November 3,

1997.

A. Federal Reserve Bank of Atlanta

(Lois Berthaume, Vice President) 104

Marietta Street, N.W., Atlanta, Georgia

30303-2713:

1. Trust No. 3 Under Will of Charles

Henderson, Troy, Alabama; to acquire at

least 79 percent of the voting shares of

Pea River Capital Corporation, Elba,

Alabama, and thereby indirectly acquire

The Peoples Bank of Coffee County,

Elba, Alabama.

B. Federal Reserve Bank of Chicago

(Philip Jackson, Applications Officer)

230 South LaSalle Street, Chicago,

Illinois 60690-1413:

1. Sparta Union Bancshares, Inc.,

Sparta, Wisconsin; to become a bank

holding company by acquiring 100

percent of the voting shares of Union

National Bnk & Trust Company, Sparta,

Wisconsin.

C. Federal Reserve Bank of St. Louis

(Randall C. Sumner, Vice President) 411

Locust Street, St. Louis, Missouri 63102-

2034:

1. First National Bancorp, Inc., Green

Forest, Arkansas; to become a bank

holding company by acquiring 100

percent of the voting shares of First

National Bank in Green Forest, Green

Forest, Arkansas.

D. Federal Reserve Bank of Kansas

City (D. Michael Manies, Assistant Vice

President) 925 Grand Avenue, Kansas

City, Missouri 64198-0001:

1. Midland First Financial

Corporation, Lee’s Summit, Missouri; to

become a bank holding company by

acquiring 100 percent of the voting

shares of Midland Bank, Lee’s Summit,

Missouri.

Board of Governors of the Federal Reserve

System, October 6, 1997.

William W. Wiles,

Secretary of the Board.

[FR Doc. 97–26854 Filed 10–8–97; 8:45 am]

BILLING CODE 6210–01–F

FEDERAL RESERVE SYSTEM

Notice of Proposals to Engage in

Permissible Nonbanking Activities or

to Acquire Companies that are

Engaged in Permissible Nonbanking

Activities

The companies listed in this notice

have given notice under section 4 of the

Bank Holding Company Act (12 U.S.C.

1843) (BHC Act) and Regulation Y, (12

CFR Part 225) to engage de novo, or to

acquire or control voting securities or

assets of a company that engages either

directly or through a subsidiary or other

company, in a nonbanking activity that

is listed in § 225.28 of Regulation Y (12

CFR 225.28) or that the Board has

determined by Order to be closely

related to banking and permissible for

bank holding companies. Unless

otherwise noted, these activities will be

conducted throughout the United States.

Each notice is available for inspection

at the Federal Reserve Bank indicated.

The notice also will be available for

inspection at the offices of the Board of

Governors. Interested persons may

express their views in writing on the

question whether the proposal complies

with the standards of section 4 of the

BHC Act.

Unless otherwise noted, comments

regarding the applications must be

received at the Reserve Bank indicated

or the offices of the Board of Governors

not later than October 23, 1997.

A. Federal Reserve Bank of

Minneapolis (Karen L. Grandstrand,

Vice President) 250 Marquette Avenue,

Minneapolis, Minnesota 55480-2171:

1. Citizens Development Co., Billings,

Montana; to engage de novo through its

subsidiary, Citizens Development Co.,

Billings, Montana, and thereby engage

in making and servicing loans, pursuant

to § 225.28(b)(1) of the Board’s

Regulation Y.
Federal Register / Vol. 62, No. 196 / Thursday, October 9, 1997 / Notices 52723

Board of Governors of the Federal Reserve

System, October 3, 1997.

William W. Wiles,

Secretary of the Board.

[FR Doc. 97–26735 Filed 10–8–97; 8:45 am]

BILLING CODE 6210–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Notice of Meetings

Notice of two meetings of the National

Bioethics Advisory Commission

(NBAC), one each of its genetics and

human subjects subcommittees, and a

brief joint session of the full

Commission.

SUMMARY: Pursuant to Section 10(d) of

the Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is given of two meetings of the National

Bioethics Advisory Commission and a

brief joint session of the full

Commission. Commission members will

discuss the protection of the rights and

welfare of human subjects in research

including decisionally and/or

cognitively impaired populations and

will address the use of genetic

information involved in tissue storage.

The meetings are open to the public and

opportunities for statements by the

public will be provided.

Dates/times Locations

Human Subjects Subcommittee, October

19, 1997, 7:30 am–

4:30 pm.

National Institutes of

Health, 9000 Rockville Pike, Building

31, 6th Floor, Conference Room 10,

Bethesda, Maryland

20892.

11:30 am–1:30 pm .... Full Commission

Meeting, Conference Room 10.

Genetics Subcommittee, October 19,

1997, 7:30 am–

4:30 pm.

National Institutes of

Health, 9000 Rockville Pike, Building

31, 6th Floor, Conference Room 9,

Bethesda, Maryland

20892.

SUPPLEMENTARY INFORMATION: The

President established the National

Bioethics Advisory Commission (NBAC)

by Executive Order 12975 on October 3,

1995 for an initial two years. An

amendment to Executive Order 12975,

dated May 16, 1997, extended the term

of the Commission for an additional two

years. The mission of the NBAC is to

advise and make recommendations to

the National Science and Technology

Council and other entities on bioethical

issues arising from the research on

human biology and behavior, and in the

applications of that research including

clinical applications.

Public Participation

All meetings are open to the public

with attendance limited by the

availability of space. Members of the

public who wish to present oral

statements should contact Ms. Patricia

Norris by telephone, fax machine, or

mail as shown below prior to the

meeting as soon as possible. Individuals

unable to make oral presentations are

encouraged to mail or fax their

comments to the NBAC staff office for

distribution to the subcommittee or

Commission members and inclusion in

the public record. Persons needing

special assistance, such as sign language

interpretation or other special

accommodations, should contact NBAC

staff at the address or telephone number

listed below as soon as possible.

FOR FURTHER INFORMATION CONTACT: Ms.

Patricia Norris, National Bioethics

Advisory Commission, MSC–7508, 6100

Executive Boulevard, Suite 5B01,

Rockville, Maryland 20892–7508,

telephone 301–402–4242, fax number

301–480–6900.

Henrietta D. Hyatt-Knorr,

Deputy Executive Director, Acting, National

Bioethics Advisory Commission.

[FR Doc. 97–26866 Filed 10–8–97; 8:45 am]

BILLING CODE 4160–17–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

Minimizing Medical Product Errors—A

Systems Approach; Public Workshop

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing a

public workshop entitled ‘‘Minimizing

Medical Product Errors—A Systems

Approach.’’ The purpose of this

workshop is to provide a forum for an

open exchange with industry, health

professionals, consumers, and others on

issues relating to minimizing the

potential for medical product errors due

to similarities in drug names, similar

labeling, design and packaging of

human drugs, biologics, blood/blood

products, vaccines, and medical

devices.

DATES: The public workshop will be

held on Thursday, January 8, 1998, 7:30

a.m. to 6 p.m. An open public hearing

to present comments, 4:15 p.m. to 5:45

p.m. Submit written abstracts by

November 7, 1997. Submit written

notices of participation by December 5,

1997. There is no registration fee for this

workshop, however, because seating is

limited interested persons are

encouraged to register by December 15,

1997.

ADDRESSES: The public workshop will

be held at Natcher Auditorium, National

Institutes of Health, 45 Center Dr.,

Bethesda, MD. Submit written abstracts

and notices of participation to Mary C.

Gross (address below).

FOR FURTHER INFORMATION CONTACT:

For general information: Mary C.

Gross, Office of External Affairs

(HF–60), Food and Drug

Administration, 5600 Fishers Lane,

rm. 14C–03, Rockville, MD 20857,

301–827–3440, FAX 301–594–0113,

e-mail

MGROSS@BANGATE.FDA.GOV.

For information regarding the

scientific paper selection process:

Jerry Phillips, Center for Drug

Evaluation and Research, 7500

Standish Pl., rm. N271, Rockville,

MD 20852, 301–827–5840, FAX

301–594–0183, e-mail

PHILLIPSJ@A1@FDACD.

SUPPLEMENTARY INFORMATION:

I. Background

FDA will explore the extent of user

error occurring with FDA-regulated

products; collect data to help FDA

determine what methods, if any, already

exist to assess the potential for medical

product errors; hear discussion from

outside groups about the appropriate

role for FDA in minimizing medical

product errors; and discuss how the

agency can effectively collaborate in

minimizing user errors.

II. Submission of the Abstracts

For purposes of discussion at the

workshop, FDA is requesting abstracts

that discuss how best to minimize the

incidence of user error with FDAregulated products. FDA will select a

limited number of abstracts that contain

information on what methods, if any,

already exist to assess the potential for

user error in relation to labeling,

packaging, and design of FDA-regulated

products for formal presentation at the

workshop.

The abstracts should be printed

(typewritten or computer) within the

confines of an 8 1/2 x 11-inch page of

white paper. All lines should be single

spaced with a three-letter indent for

each paragraph. The title should be brief

and capitalized. The authors name(s)

should then be listed, underlining each,

then list agency, institution, or facility

involved.